EUVIMEDEUVIMED entdecken
Crossref

Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?

Lucas M.D. Espíndola, Renata M. Salhab, Carlos Dos Anjos, Bernardo Garicochea, Rodrigo R. Munhoz

Clinical Skin Cancer · 2017-12 · 2 (1-2) · 10-17

DOI: 10.1016/j.clsc.2017.06.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Skin Cancer, 2017-12. Verfasst von Lucas M.D. Espíndola und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Espíndola, L. M., Salhab, R. M., Anjos, C. D., Garicochea, B., & Munhoz, R. R. (2017). Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. Clinical Skin Cancer, 2(1-2), 10-17. https://doi.org/10.1016/j.clsc.2017.06.003

Vancouver

Espíndola LM, Salhab RM, Anjos CD, Garicochea B, Munhoz RR. Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. Clinical Skin Cancer. 2017;2(1-2):10-17. doi:10.1016/j.clsc.2017.06.003

BibTeX
@article{Espndola2017,
  author = {Espíndola, Lucas M.D. and Salhab, Renata M. and Anjos, Carlos Dos and Garicochea, Bernardo and Munhoz, Rodrigo R.},
  title = {Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?},
  journal = {Clinical Skin Cancer},
  year = {2017},
  volume = {2},
  number = {1-2},
  pages = {10--17},
  doi = {10.1016/j.clsc.2017.06.003}
}
Kostenlos starten →